Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two substances: **opium**, a natural mixture of alkaloids derived from the poppy plant (Papaver somniferum), and **ethyl iodide** (also known as iodoethane), an organoiodine compound. \n- **Opium** acts primarily as an agonist at opioid receptors in the central nervous system, producing analgesia, sedation, euphoria, respiratory depression, constipation, and other effects. Its main active components include morphine, codeine, thebaine, papaverine, and noscapine. The pharmacological effects are mediated through activation of μ-opioid (mu), δ-opioid (delta), and κ-opioid (kappa) receptors[1][5]. \n- **Ethyl iodide** is a small molecule used mainly as an ethylating agent in organic synthesis; it has no established therapeutic use or recognized mechanism of action in medicine[6]. It is not known to have any direct pharmacological effect relevant to human therapy.\n\nThere is no evidence that this specific combination has been developed or marketed for medical use. No unique brand name or clinical indication for "opium + ethyl iodide" exists in standard drug references.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on opium + ethyl iodide.